Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.83
-4.28 (-2.04%)
AAPL  264.44
-0.14 (-0.05%)
AMD  197.32
-2.83 (-1.42%)
BAC  52.92
-0.14 (-0.26%)
GOOG  316.01
+1.11 (0.35%)
META  649.50
-6.16 (-0.94%)
MSFT  388.54
-8.69 (-2.19%)
NVDA  192.84
+3.02 (1.59%)
ORCL  141.97
-6.11 (-4.13%)
TSLA  403.24
-8.58 (-2.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.